Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Indication

Endometrial Cancer

Clinical and regulatory intelligence for Endometrial Cancer with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
6
Catalysts
0
Assets
4

Relevant assets

dostarlimab →
Olaparib →
Phase →
RBM15B →

Relevant companies

AstraZeneca →
oncology pharmaceutical companies →

Recent signals(6)

ClinicalAugust 3, 2026

Study on MR-Guided Adaptive Therapy for Endometrial Cancer Initiated

A clinical trial is evaluating the safety and efficacy of MR-guided adaptive pelvic IMRT in endometrial cancer patients.

Strategy
August 2, 2026

Budget Impact of Dostarlimab in First-Line Endometrial Cancer Treatment in Saudi Arabia

The budget impact of dostarlimab combined with carboplatin-paclitaxel as a first-line treatment for endometrial cancer was assessed.

ClinicalJuly 26, 2026

Study Compares Semaglutide, Surgery, and Lifestyle for Weight Management in Endometrial Cancer

The study evaluates the effectiveness of sleeve gastrectomy, semaglutide, and a lifestyle program for weight management in endometrial cancer patients.

ClinicalJuly 21, 2026

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Mutant Endometrial Cancer

A Phase Ib trial is underway to evaluate the safety and dosing of a combination therapy for RAS pathway mutant endometrial cancer.

ClinicalJuly 7, 2026

RBM15B/FOXM1/AURKA/TPX2 axis identified as key driver in endometrial cancer progression

RBM15B-mediated m6A modification of FOXM1 promotes endometrial cancer progression via the AURKA/TPX2 axis.

ClinicalJune 18, 2026

Phase II Trial of Olaparib and Durvalumab Combinations in Recurrent Endometrial Cancer

A phase II trial is evaluating the efficacy of combinations of olaparib, durvalumab, cediranib, and capivasertib in recurrent or refractory endometrial cancer.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Endometrial Cancer →
Oncology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.